{"entity":{"id":"paper-monitor-breast-foldi-future-oncol-2026","kind":"paper","name":"MONITOR-Breast: whole-genome ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes","aka":[],"tldr":"In 154 people having drug treatment before breast cancer surgery, a whole-genome blood test for tumour DNA was negative after treatment in everyone whose tumour had fully disappeared, and staying positive went with cancer left at surgery.","summary":"A prospective observational study of 154 patients with stage I-III breast cancer of all subtypes, tested at baseline, throughout neoadjuvant therapy and after surgery with a whole-genome sequencing-based residual disease assay tracking up to 1,000 variants per patient. Myriad Genetics announced the publication on 23 June 2026 as evidence for the clinical validity of its Precise MRD test.","asOf":"2026-11-03","links":[{"label":"Future Oncology 2026","url":"https://doi.org/10.1080/14796694.2026.2690165"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42324681/"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":["precise-mrd"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"journal":"Future Oncology","year":2026,"doi":"10.1080/14796694.2026.2690165","pmid":"42324681","authors":"Foldi J, Hogan G, Johansen Taber K, et al.","paperType":"observational","findings":["Baseline ctDNA was detected in 93% of patients, 20% of them in the ultrasensitive range below 100 parts per million.","Post-treatment ctDNA positivity was strongly associated with residual disease at surgery (odds ratio above 20) and with positivity after the operation (odds ratio 47).","All 56 patients with a pathological complete response and an evaluable sample had undetectable ctDNA after neoadjuvant therapy.","22% had persistent or intermittent positivity and significantly more residual disease (odds ratio 52)."],"whatItMeans":"Frequent, very sensitive blood tests for tumour DNA during treatment before surgery track how well the treatment is working; the authors see a chance to do less for early responders and more for those whose ctDNA persists, which trials would need to test.","caveats":["A prospective observational study: it reports associations and does not test whether acting on the result changes outcomes."],"participants":154},"route":"/key-papers/paper-monitor-breast-foldi-future-oncol-2026/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"precise-mrd","kind":"drug","name":"Precise MRD","route":"/drugs/precise-mrd/"}],"journal":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/"}]}}